Merck & Co's Keytruda blockbuster immunotherapy could have yet another use, after it significantly boosted survival in patients with untreated squamous non-small cell lu
Merck & Co's cancer drug Keytruda has been granted a priority review so that the immunotherapy medicine can be used in conjunction with chemotherapy to improve survival rates for untrea
AstraZeneca had placed its immunotherapy Imfinzi (durvalumab) at the centre of its efforts to rebuild its sales – but after a shock failure last year in first line lung cancer, the drug has
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
